Valuation: EnteroMedics Inc

Market Cap 1.58Cr 1.39Cr 1.28Cr 1.18Cr 2.23Cr 151.15Cr 2.28Cr 15Cr 6Cr 74Cr 5.93Cr 5.8Cr 256.33Cr P/E 2026 *
-3.19x
P/E 2027 * -2.46x
Enterprise Value 1.58Cr 1.39Cr 1.28Cr 1.18Cr 2.23Cr 151.15Cr 2.28Cr 15Cr 6Cr 74Cr 5.93Cr 5.8Cr 256.33Cr EV / Sales 2026 *
105x
EV / Sales 2027 * 63.2x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 2L 1L 1L 1L 2L 1.44Cr 2L 14.52L 6L 70.5L 6L 6L 2.43Cr 2L 2L 2L 2L 4L 2.39Cr 4L 24.21L 9L 1.18Cr 9L 9L 4.06Cr
Net income -48.9L -42.89L -39.72L -36.55L -69.13L -47Cr -70.48L -4.73Cr -1.86Cr -23Cr -1.84Cr -1.8Cr -79Cr -77.69L -68.14L -63.11L -58.07L -1.1Cr -74Cr -1.12Cr -7.52Cr -2.95Cr -37Cr -2.92Cr -2.85Cr -126.11Cr
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-